Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.84 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.84 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.84 |
| ▸ | MAPT | P10636 | 3/20 | 0.80 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | FABP3 | P05413 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | GMNN | O75496 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | BLM | P54132 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15477711 | 1.00 | SMN1; SMN2 (0.84) | SMN1; SMN2NR5A2NR5A1MAPTRECQL | |
| SCHEMBL15477474 | 1.00 | SMN1; SMN2 (0.84) | SMN1; SMN2NR5A2NR5A1MAPTRECQL | |
| SCHEMBL15477746 | 1.00 | SMN1; SMN2 (0.84) | SMN1; SMN2NR5A2NR5A1MAPTRECQL | |
| SCHEMBL1292651 | 1.00 | SMN1; SMN2 (0.84) | SMN1; SMN2NR5A2NR5A1MAPTRECQL | |
| SCHEMBL15477633 | 1.00 | SMN1; SMN2 (0.84) | SMN1; SMN2NR5A2NR5A1MAPTRECQL | |
| SCHEMBL2370478 | 1.00 | SMN1; SMN2 (0.84) | SMN1; SMN2NR5A2NR5A1MAPTRECQL | |
| SCHEMBL159631 | 1.00 | SMN1; SMN2 (0.84) | SMN1; SMN2NR5A2NR5A1MAPTRECQL | |
| SCHEMBL9951509 | 1.00 | SMN1; SMN2 (0.84) | SMN1; SMN2NR5A2NR5A1MAPTRECQL | |
| SCHEMBL15477814 | 1.00 | SMN1; SMN2 (0.84) | SMN1; SMN2NR5A2NR5A1MAPTRECQL | |
| SCHEMBL15477665 | 1.00 | SMN1; SMN2 (0.84) | SMN1; SMN2NR5A2NR5A1MAPTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12576037-B2 | Polymer-encapsulated drug particles | TONIC MEDICAL, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4106828-B1 | POLYMER-ENCAPSULATED DRUG PARTICLES | TONIC MEDICAL INC (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4678198-A2 | POLYMER-ENCAPSULATED DRUG PARTICLES | Tonic Medical, Inc. (US) | 2026-01-14 | — | — | EP | claimed |
| US-20250268839-A1 | PROMOTING TRAINED IMMUNITY WITH THERAPEUTIC NANOBIOLOGIC COMPOSITIONS | STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM (NL) | 2025-08-28 | — | — | US | claimed |
| US-20250205262-A1 | SPHINGOLIPID-LOADED NANOBIOLOGICS FOR IMMUNE REGULATION | STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM (NL) | 2025-06-26 | — | — | US | claimed |
| US-12329815-B2 | Acoustic driven drug delivery systems | UNIVERSITY OF OTAGO (NZ) | 2025-06-17 | — | — | US | claimed |
| CN-119630391-A | Sphingolipid-loaded nanobiological formulation for immunomodulation | 西奈山伊坎医学院 | 2025-03-14 | — | — | CN | claimed |
| US-20240315976-A1 | POLYMER-ENCAPSULATED DRUG PARTICLES | TONIC MEDICAL, INC. | 2024-09-26 | — | — | US | claimed |
| EP-4370158-A1 | PORPHYRIN NANOVESICLE WITH FATTY ACID CONJUGATE | University Health Network (CA) | 2024-05-22 | — | — | EP | claimed |
| US-20240131227-A1 | MULTIFUNCTIONAL SEALING MEMBER FOR IMPROVED ENDOTHELIALIZATION AND PARAVALVULAR LEAKAGE | EDWARDS LIFESCIENCES CORP (US) | 2024-04-25 | — | — | US | claimed |
| EP-4106828-A1 | POLYMER-ENCAPSULATED DRUG PARTICLES | GIE Medical, Inc. (US) | 2022-12-28 | — | — | EP | claimed |
| CN-115461096-A | Polymer encapsulated drug particles | 吉益医疗公司 | 2022-12-09 | — | — | CN | claimed |
| US-20220143182-A1 | ACOUSTIC DRIVEN DRUG DELIVERY SYSTEMS | UNIVERSITY OF OTAGO (NZ) | 2022-05-12 | — | — | US | claimed |
| US-11260126-B2 | Acoustic driven drug delivery systems | UNIVERSITY OF OTAGO (NZ) | 2022-03-01 | — | — | US | claimed |
| EP-3285814-B1 | IMAGING OF TUMOR-ASSOCIATED MACROPHAGES | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-06-24 | — | — | EP | claimed |
| US-20180236075-A1 | ACOUSTIC DRIVEN DRUG DELIVERY SYSTEMS | UNIVERSITY OF OTAGO (NZ) | 2018-08-23 | — | — | US | claimed |
| US-20180140725-A1 | IMAGING OF TUMOR-ASSOCIATED MACROPHAGES | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2018-05-24 | — | — | US | claimed |
| EP-3285814-A1 | IMAGING OF TUMOR-ASSOCIATED MACROPHAGES | Memorial Sloan-Kettering Cancer Center (US) | 2018-02-28 | — | — | EP | claimed |
| US-20170128591-A1 | Peptide Containing Porphyrin Lipid Nanovesicles | UNIVERSITY HEALTH NETWORK (CA) | 2017-05-11 | — | — | US | claimed |
| WO-2016172146-A1 | IMAGING OF TUMOR-ASSOCIATED MACROPHAGES | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2016-10-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250205262-A1 | SPHINGOLIPID-LOADED NANOBIOLOGICS FOR IMMUNE REGULATION | APOB, APOL1, SGMS1 | SMN1; SMN2 962/4885NR5A2 2894/4885NR5A1 2980/4885 |
| US-12576037-B2 | Polymer-encapsulated drug particles | PHOSPHO1, SGMS1, SGMS2 | SMN1; SMN2 578/4885NR5A2 3443/4885NR5A1 3606/4885 |
| US-12329815-B2 | Acoustic driven drug delivery systems | PARK7, NLN, OPA1 | SMN1; SMN2 305/4885NR5A2 3084/4885NR5A1 3957/4885 |
| US-20220143182-A1 | ACOUSTIC DRIVEN DRUG DELIVERY SYSTEMS | PARK7, NLN, OPA1 | SMN1; SMN2 305/4885NR5A2 3084/4885NR5A1 3957/4885 |
| US-11260126-B2 | Acoustic driven drug delivery systems | LSS, LIPA, MTREX | SMN1; SMN2 3006/4885NR5A2 1688/4885NR5A1 2050/4885 |
| US-20240315976-A1 | POLYMER-ENCAPSULATED DRUG PARTICLES | CD47, GRPR, HSPA5 | SMN1; SMN2 468/4885NR5A2 2470/4885NR5A1 2929/4885 |
| US-20180236075-A1 | ACOUSTIC DRIVEN DRUG DELIVERY SYSTEMS | LSS, LIPA, MTREX | SMN1; SMN2 3006/4885NR5A2 1688/4885NR5A1 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.